Clinical trials: Cannabidiol
Cannabis Use Disorder
Cannabidiol: a Novel Intervention for Cannabis Use Problems?
The purpose of this trial is to investigate a novel treatment for cannabis dependence: cannabidiol. Between 96 and 168 young people who want to quit cannabis and meet criteria for moderate cannabis use disorder (DSM-5) will be…
- Trial name
- NCT02044809
- Testing
- Cannabidiol
- Where
- United Kingdom
- Volunteers
- 82 people
- Sponsor
- University College, London
Fatty Liver
Study to Evaluate the Effect of GWP42003 on Liver Fat Levels in Participants With Fatty Liver Disease
The purpose of this study is to evaluate the effect of GWP42003 on liver triglyceride (liver fat) in participants with fatty liver disease (FLD).
- Trial name
- NCT01284634
- Testing
- GWP42003 200 mg/day Dose, GWP42003 400 mg/day Dose, GWP42003 800 mg/day Dose
- Where
- 3 sites in United Kingdom
- Volunteers
- 25 people
- Sponsor
- GW Research Ltd
Cannabis, Chronic Kidney Diseases
The Pharmacokinetics of Single Dose Oral Tetrahydrocannabinol and Cannabidiol
POT-GFR-PK is a single dose pharmacokinetic study oral tetrahydrocannabinol (THC) and cannabidiol (CBD) in healthy adult controls and individuals with chronic kidney disease including those treated with in-center hemodialysis.
- Conditions
- Cannabis, Chronic Kidney Diseases, Dialysis
- Trial name
- POT-GFR-PK (NCT05742724)
- Testing
- Tetrahydrocannabinol-Cannabidiol Combination
- Where
- Canada
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- McMaster University
Fragile X Syndrome
Clinical Study Of caNNabidiol in childrEn and adolesCenTs With Fragile X (CONNECT-FX)
This trial will evaluate the efficacy and safety of ZYN002, a clear cannabidiol gel that can be applied to the skin (called transdermal application) twice a day for the treatment of behavioral symptoms of Fragile X Syndrome…
- Trial name
- CONNECT-FX (NCT03614663)
- Testing
- ZYN002 - Cannabidiol Transdermal Gel
- Where
- 21 sites in United States, Australia and 1 more
- Volunteers
- 212 people
- Sponsor
- Zynerba Pharmaceuticals, Inc.
Pain, Postoperative
The Use of Cannabidiol (CBD) in Pain Reduction and Opioid Use After Shoulder Arthroscopy
This study is designed to evaluate the effects of administering CBD to control post-operative pain in patients undergoing shoulder arthroscopy.
- Trial name
- NCT04672252
- Testing
- CBD Oral Disintegrating Tablet (ODT)
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- NYU Langone Health
Bipolar Disorder
Cannabidiol for Bipolar Depression (CBD-BD)
Bipolar disorder (BD) is a lifelong condition characterized by recurrent episodes of depression and (hypo)mania. Periods of chronic and recurring depressive episodes are more common and can be severely disabling.
- Trial name
- CBD-BD (NCT05867849)
- Testing
- Cannabidiol
- Where
- 6 sites in Canada
- Volunteers
- 360 people
- Sponsor
- University of British Columbia
Autoimmune Hepatitis
A Phase 2a Study to Evaluate the Safety and Efficacy of Cannabidiol Only as Maintenance Therapy and Steroid Sparing in Patients With Stable Autoimmune Hepatitis
Subjects with stable autoimmune hepatitis disease currently being administered corticosteroids with or without azathioprine (AZA) treatment will be be treated with Cannabidiol instead of standard of care treatment with…
- Trial name
- NCT04129489
- Testing
- Cannabidiol
- Where
- Israel
- Volunteers
- 2 people
- Sponsor
- Stero Biotechs Ltd.
Early Psychosis
Effects of Cannabidiol (CBD) Versus Placebo as an Adjunct to Treatment in Early Psychosis
This is an outpatient, single center, between-group, double blind, placebo controlled design. Approximately 120 adolescents and adult patients will be randomized to either have their treatment augmented with Cannabidiol Oral…
- Trial name
- NCT04411225
- Testing
- Cannabidiol oral solution
- Where
- 2 sites in United States
- Volunteers
- 120 people
- Sponsor
- University of California, San Diego
Muscle Soreness
Topical CBD's Effects on Soreness and Performance
Exercise-induced muscle damage (EIMD) results from unaccustomed exercise and can lead to delayed onset muscle soreness (DOMS). Impairments associated with EIMD and DOMS can result in moderate-to-severe discomfort and hindered…
- Trial name
- NCT06320327
- Testing
- Cannabidiol cream
- Where
- 2 sites in United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Joseph Pastina
Drug Resistant Epilepsy
Study of Cannabidiol for Drug-Resistant Epilepsies
The purpose of this study is to determine if cannabidiol is safe and effective at different doses as an additional treatment for pediatric drug-resistant epilepsy.
- Trial name
- NCT03014440
- Testing
- Cannabidiol
- Sponsor
- Eric Marsh, MD
Alcohol Withdrawal, Alcohol Dependence
Cannabidiol (CBD) for the Treatment of Alcohol Withdrawal
This study will explore the effectiveness and tolerability of Cannabidiol (CBD) in the treatment of alcohol withdrawal symptoms in an inpatient setting, in a double-blind randomised placebo-controlled trial.
- Trial name
- NCT04205682
- Testing
- Cannabidiol
- Where
- 2 sites in Australia
- Volunteers
- 52 people
- Sponsor
- South West Sydney Local Health District
Cannabis Use Disorder
Longitudinal Outpatient Treatment for Cannabis Use Disorder
This study is a placebo-controlled randomized trial comparing the effects of hemp-derived cannabidiol (CBD) with and without Delta-9-tetrahydrocannabinol (THC), relative to placebo, on reducing cannabis use and cannabis use…
- Trial name
- LOTUS (NCT06107062)
- Testing
- Cannabidiol - fsCBD, Cannabidiol - bsCBD
- Where
- United States
- Volunteers
- 165 people
- Sponsor
- University of Colorado, Boulder
Schizophrenia, Schizoaffective Disorder
Cannabidiol Treatment in Patients With Early Psychosis
Cannabidiol (CBD) is a component of herbal cannabis that is present in varying concentrations in cannabis extracts. CBD has been shown to produce central effects including hypnotic, anticonvulsive, anxiolytic and neuroprotective…
- Trial name
- CBD (NCT02504151)
- Testing
- Cannabidiol
- Where
- 2 sites in United States
- Volunteers
- 18 people
- Sponsor
- Yale University
Alcohol Use Disorder
Cannabidiol for Reducing Drinking in Alcohol Use Disorder
The non-psychotomimetic cannabis compound cannabidiol (CBD) has been found effective for reducing alcohol drinking in mice. Moreover, other experimental studies have found that CBD reduced alcohol-induced steatosis in the liver…
- Trial name
- CARAMEL (NCT05159830)
- Testing
- Cannabidiol oral oil
- Where
- France
- Volunteers
- 10 people
- Sponsor
- Hôpital le Vinatier
Cannabis
A Study of Inhaled Cannabidiol in Healthy Occasional Cannabis Users
The purposes of this study are 1) to determine if the administration of different low doses of CBD (5 mg, 20 mg, 50 mg and 100 mg) result in detectable subjective pleasant drug effect compared to placebo and 2) to qualitatively…
- Trial name
- NCT05320367
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Centre hospitalier de l'Université de Montréal (CHUM)
Cannabis, Drug Effects
The Pharmacokinetic and Pharmacodynamic Effects of Oral Cannabidiol (CBD) Under Acute and Chronic Exposure Conditions
This study will evaluate the pharmacokinetic and pharmacodynamic effects of oral Cannabidiol (with or without low levels of THC), under acute and chronic dosing conditions.
- Trial name
- NCT04283019
- Testing
- CBD, THC
- Where
- United States
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
CBD, Healthy
CBD-Microglia PET Study
This study aims to examine the effect of cannabidiol (CBD) pre-treatment on brain microglial activation in healthy human subjects.
- Trial name
- NCT04398719
- Testing
- [11C]PBR28, Low-dose lipopolysaccharide, Intradermal Capsaicin
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Yale University
Anxiety and Fear
Impact of CBD-Rich Oil on Aversive Memory Reconsolidation
The purpose of this study is to test whether cannabidiol (CBD) rich hemp extract oil can interfere with the reconsolidation (storage) of pathological fear memory in humans.
- Trial name
- NCT04726475
- Testing
- Interoceptive Aversive Memory Reactivation, Cannabidiol (CBD)-Rich Broad Spectrum Hemp Extract Oil
- Where
- United States
- Volunteers
- 96 people
- Sponsor
- University of Texas at Austin
Alcohol Drinking, Cannabis Use
Cannabis' Impact on Alcohol Consumption
This study employs a repeated measures experimental design to examine the effect of THC-dominant dose of cannabis and CBD-dominant dose of cannabis, relative to placebo, on subsequent drinking in an alcohol choice task in which…
- Conditions
- Alcohol Drinking, Cannabis Use, Cannabis, Alcohol Use Disorder
- Trial name
- NCT05389930
- Testing
- THC-dominant cannabis, CBD-dominant cannabis, Alcohol
- Where
- United States
- Volunteers
- 350 people, healthy volunteers welcome
- Sponsor
- Brown University
Cannabis Use Disorder
Cannabidiol Pharmacotherapy for Adults With Cannabis Use Disorder
Investigators aim to determine Epidiolex's promise as a pharmacotherapy for cannabis use disorder. Investigators hypothesize that Epidiolex, when added to medical management, will result in greater reductions in marijuana use…
- Trial name
- CBD (NCT03102918)
- Testing
- Cannabidiol
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Mclean Hospital